On Tuesday, BTIG downgraded shares of Akoya Biosciences Inc (NASDAQ: AKYA) from Buy to Neutral. The analytical firm cited a series of concerns following the company's announcement of its third workforce reduction in 13 months, along with a decrease in its 2024 revenue forecast for two consecutive quarters.
The downgrade reflects apprehensions about the potential for Akoya to achieve meaningful revenue growth in the near future.
The company's recent moves have raised investor concerns regarding several issues. These include limited budgets within the tools market, extended selling cycles, uncertain timing for profitability, and increasing competition.
The repeated reduction in workforce ahead of investments for business growth has also sparked worries about the impact on employee morale and motivation.
The firm's decision to downgrade Akoya's rating is a response to the latest revenue guidance cut and additional workforce reduction. This combination of factors has led to the belief that it will take longer for investors, including the analysts at BTIG, to witness Akoya returning to significant revenue growth.
BTIG expressed concerns about the company's board and management strategies, particularly the prioritization of headcount cuts over investments aimed at expanding the business. This approach has raised questions about Akoya's capability to re-establish a growth trajectory by 2025.
InvestingPro Insights
Amid the recent downgrade by BTIG, current metrics from InvestingPro show a challenging financial landscape for Akoya Biosciences Inc. With a market capitalization of $106.18 million, Akoya's price-to-earnings (P/E) ratio stands at a negative 1.46, indicating that the company is not currently generating profits. In line with BTIG's concerns, the InvestingPro Tips suggest that Akoya is quickly burning through cash and has not been profitable over the last twelve months, which may contribute to the analysts' skepticism about the company's near-term revenue growth potential.
Furthermore, Akoya's stock has experienced a significant decline over the past week, with a one-week price total return of -12.96%. The three-month return has been even more pronounced, with the stock value dropping by 47.82%. This volatility is noteworthy for investors considering the stock's performance and future outlook. Despite these challenges, it's important to note that the company's liquid assets still exceed short-term obligations, providing some financial flexibility in the immediate future.
For those interested in a deeper analysis, there are additional InvestingPro Tips available, which can be found on the InvestingPro platform. These tips provide insights into Akoya's financial health and market position, which can be crucial for making informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.